دورية أكاديمية
أعرض في EDS

Acute mortality in critically ill patients undergoing echocardiography with or without an ultrasound contrast agent.

التفاصيل البيبلوغرافية
العنوان: Acute mortality in critically ill patients undergoing echocardiography with or without an ultrasound contrast agent.
المؤلفون: Main ML; Saint Luke's Mid America Heart Institute, Kansas City, Missouri. Electronic address: mmain@saint-lukes.org., Hibberd MG; Lantheus Medical Imaging, Inc., North Billerica, Massachusetts., Ryan A; Premier, Inc., Charlotte, North Carolina., Lowe TJ; Premier, Inc., Charlotte, North Carolina., Miller P; Lantheus Medical Imaging, Inc., North Billerica, Massachusetts., Bhat G; Lantheus Medical Imaging, Inc., North Billerica, Massachusetts.
المصدر: JACC. Cardiovascular imaging [JACC Cardiovasc Imaging] 2014 Jan; Vol. 7 (1), pp. 40-8. Date of Electronic Publication: 2013 Nov 27.
نوع المنشور: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101467978 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1876-7591 (Electronic) Linking ISSN: 18767591 NLM ISO Abbreviation: JACC Cardiovasc Imaging Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York : Elsevier
مواضيع طبية MeSH: Contrast Media*, Critical Illness/*mortality , Echocardiography/*methods, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Cause of Death/trends ; Female ; Follow-Up Studies ; Hospital Mortality/trends ; Humans ; Length of Stay/trends ; Male ; Middle Aged ; Odds Ratio ; Prognosis ; Propensity Score ; Retrospective Studies ; Risk Factors ; Survival Rate/trends ; United States/epidemiology ; Young Adult
مستخلص: Objectives: The objective of this observational study was to compare 48-h all-cause mortality (as well as hospital stay mortality) among critically ill patients who underwent echocardiography either with or without an ultrasound contrast agent (UCA).
Background: The safety of perflutren-based UCAs has been questioned by the U.S. Food and Drug Administration (particularly when administered to critically ill patients) following rare reports of deaths or life-threatening adverse reactions that occurred in close temporal relationship to UCA administration.
Methods: This was a retrospective observational outcome study conducted in critically ill patients to compare all-cause 48-h and hospital stay mortality subsequent to echocardiography procedures performed either with or without a UCA. The study utilized discharge data from a database maintained by Premier, Inc. (Charlotte, North Carolina). Premier's database is the largest U.S. hospital-based, service-level comparative database for quality and outcomes research, and provides detailed resource utilization data along with patients' primary and secondary diagnoses and procedure billing codes. A propensity score-matching algorithm between UCA-enhanced echocardiography patients and non-contrast-enhanced echocardiography patients was utilized to reduce the potential for imbalance in covariates of selected patients in the comparison of mortality between groups.
Results: Patients undergoing echocardiography with a UCA had lower mortality at 48 h compared with patients undergoing non-contrast-enhanced echocardiography (1.70% vs. 2.50%), with an odds ratio = 0.66 (95% confidence interval [CI]: 0.54 to 0.80). Patients undergoing echocardiography with a UCA had lower hospital stay mortality compared with patients undergoing noncontrast echocardiography (14.85% vs. 15.66%), with an odds ratio = 0.89 (95% CI: 0.84 to 0.96).
Conclusions: In critically ill, propensity-matched hospitalized patients undergoing echocardiography, use of a UCA is associated with a 28% lower mortality at 48 h in comparison with patients undergoing non-contrast-enhanced echocardiography. These results are reassuring, given previous reports suggesting an association between UCAs and increased mortality in critically ill patients.
(Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
فهرسة مساهمة: Keywords: APR-DRG; All Patient Refined Diagnosis Related Group; CI; FDA; Food and Drug Administration; ICU; TTE; UCA; cTTE; confidence interval; contrast echocardiography; contrast enhanced ultrasound; contrast-enhanced transthoracic echocardiography; intensive care unit; nTTE; non–contrast-enhanced transthoracic echocardiography; transthoracic echocardiography; ultrasound contrast agent; ultrasound contrast agents
المشرفين على المادة: 0 (Contrast Media)
تواريخ الأحداث: Date Created: 20131203 Date Completed: 20150106 Latest Revision: 20210503
رمز التحديث: 20240628
DOI: 10.1016/j.jcmg.2013.08.012
PMID: 24290568
قاعدة البيانات: MEDLINE
الوصف
تدمد:1876-7591
DOI:10.1016/j.jcmg.2013.08.012